STAAR Surgical Company (NASDAQ:STAA) Files An 8-K Other Events
Item 8.01 Other Events.
On May 11, 2017, STAAR Surgical Company (the Company) filed a
universal shelf registration statement on Form S-3 with the
Securities and Exchange Commission (SEC). The Companys existing
universal shelf registration statement expires on May 12, 2017.
The registration statement is subject to review by the SEC.
When declared effective by the SEC, the shelf registration will
allow the Company the flexibility to offer and sell up to $200
million of securities, including common stock, preferred stock,
debt securities, and warrants, from time to time and through
various methods of distribution. The Companys existing universal
shelf registration statement also authorized the Company to issue
up to $200 million of securities. In accordance with SEC rules,
the Company may make securities offerings under the existing
shelf registration statement until the new registration statement
is declared effective, subject to a maximum extension of 180
days. There are no plans to offer securities under either shelf
registration statement at this time. Any future offering would be
subject to market conditions and approval by the Companys Board
of Directors. Any offering of securities covered by a shelf
registration statement will be made only by means of a prospectus
supplement authorized and filed by the Company.
The registration statement has been filed with the SEC but has
not yet become effective. The securities being registered may not
be sold, nor may offers to buy be accepted, prior to the time the
registration statement becomes effective.
About STAAR Surgical Company (NASDAQ:STAA)
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses (IOLs) used in cataract surgery and implantable collamer lenses (ICLs) used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). It sells its products in approximately 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world. STAAR Surgical Company (NASDAQ:STAA) Recent Trading Information
STAAR Surgical Company (NASDAQ:STAA) closed its last trading session down -0.20 at 9.45 with 63,945 shares trading hands.
